Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rashid Kazerooni

Showing results (1-10 of 33) with videos related to

Pageof 4
Sort By:
Journal of Family Medicine and Primary Care|November 10, 2022
Letter to the editor regarding "Selfies: A boon or bane?"Rashid Kazerooni
Journal of Drug Assessment|August 19, 2016
Predictors of long-term mortality in new start statin usersRashid Kazerooni, Jane Lim
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|January 30, 2015
Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystoniaRashid Kazerooni, Christine Broadhead
Military Medicine|March 2, 2016
Topiramate-Associated Weight Loss in a Veteran PopulationRashid Kazerooni, Jane Lim
Clinicoeconomics and Outcomes Research : CEOR|September 22, 2011
Cost-effectiveness analysis of intravenous levetiracetam versus intravenous phenytoin for early onset seizure prophylaxis after neurosurgery and traumatic brain injuryRashid Kazerooni, Mark Bounthavong
The Clinical Journal of Pain|November 8, 2014
Evaluation of Celecoxib Addition to Pain Protocol After Total Hip and Knee Arthroplasty Stratified by Opioid ToleranceRashid Kazerooni, Michael H Tran
Clinical Drug Investigation|November 4, 2018
Response to "Comment on: Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database"Rashid Kazerooni, Edward P Armstrong
Journal of Managed Care & Specialty Pharmacy|January 29, 2021
Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare populationRashid Kazerooni, Jonathan H Watanabe
Clinical Drug Investigation|June 22, 2018
Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System DatabaseRashid Kazerooni, Edward P Armstrong
Peerj|June 3, 2014
Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran populationMark Bounthavong, Nermeen Madkour, Rashid Kazerooni
Pageof 4

Showing results (1-10 of 33) with videos related to

Sort By:
Pageof 4
Journal of Family Medicine and Primary Care|November 10, 2022
Letter to the editor regarding "Selfies: A boon or bane?"Rashid Kazerooni
Journal of Drug Assessment|August 19, 2016
Predictors of long-term mortality in new start statin usersRashid Kazerooni, Jane Lim
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|January 30, 2015
Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystoniaRashid Kazerooni, Christine Broadhead
Military Medicine|March 2, 2016
Topiramate-Associated Weight Loss in a Veteran PopulationRashid Kazerooni, Jane Lim
Clinicoeconomics and Outcomes Research : CEOR|September 22, 2011
Cost-effectiveness analysis of intravenous levetiracetam versus intravenous phenytoin for early onset seizure prophylaxis after neurosurgery and traumatic brain injuryRashid Kazerooni, Mark Bounthavong
The Clinical Journal of Pain|November 8, 2014
Evaluation of Celecoxib Addition to Pain Protocol After Total Hip and Knee Arthroplasty Stratified by Opioid ToleranceRashid Kazerooni, Michael H Tran
Clinical Drug Investigation|November 4, 2018
Response to "Comment on: Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database"Rashid Kazerooni, Edward P Armstrong
Journal of Managed Care & Specialty Pharmacy|January 29, 2021
Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare populationRashid Kazerooni, Jonathan H Watanabe
Clinical Drug Investigation|June 22, 2018
Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System DatabaseRashid Kazerooni, Edward P Armstrong
Peerj|June 3, 2014
Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran populationMark Bounthavong, Nermeen Madkour, Rashid Kazerooni
Pageof 4